Improved survival of follicular lymphoma patients in the United States.
about
Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphomaUpdate on the rational use of Y-ibritumomab tiuxetan in the treatment of follicular lymphomaFollicular lymphoma: 2011 update on diagnosis and managementIsotype-switched follicular lymphoma displays dissociation between activation-induced cytidine deaminase expression and somatic hypermutationA phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma.Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.Nature and importance of follicular lymphoma precursors.Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registryWeekly versus biweekly bortezomib given in patients with indolent non-Hodgkin lymphoma: A meta-analysisPrognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study.Outcomes for lymphoid malignancies in the Nurses' Health Study (NHS) as compared to the Surveillance, Epidemiology and End Results (SEER) Program.High baseline serum thymidine kinase 1 level predicts unfavorable outcome in patients with follicular lymphoma.The role of bendamustine in the treatment of indolent non-Hodgkin lymphomaRituximab maintenance in relapsed or refractory follicular non-Hodgkin's lymphoma: the evidence of its therapeutic value.Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma.Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphomaElevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma.Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901Economic impact of disease progression in follicular non-Hodgkin lymphoma.Highly clonal regulatory T-cell population in follicular lymphoma - inverse correlation with the diversity of CD8(+) T cells.C-MOPP: the forgotten regimen plus Rituximab for untreated and relapsed follicular lymphoma.Exploring risk factors for follicular lymphoma.Contributions of Subtypes of Non-Hodgkin Lymphoma to Mortality TrendsFollicular lymphoma: today's treatments and tomorrow's targets.Tumor suppressor gene methylation in follicular lymphoma: a comprehensive reviewEconomic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphomaImmunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis.BiovaxID idiotype vaccination: active immunotherapy for follicular lymphoma.High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era.Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma : a NICE single technology appraisal.Update on front-line therapy for follicular lymphoma: chemo-immunotherapy with rituximab and survival.Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study.Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.Monoclonal antibodies in lymphoma: the first decade.Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party.Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols.Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience.Hematopoietic stem cell transplantation for the management of follicular lymphoma
P2860
Q24243100-6921B1B9-49E7-4AC1-B48E-429C7954FD51Q24633710-37A66F4B-510E-4FCD-BEC4-989E829C4783Q26851450-01B6C4FA-9C89-4824-94D7-9B0B7410A1CEQ28260230-276365E5-2ADA-43BA-8772-5EE95A926729Q30538453-91F655D1-8A2C-4793-A9D6-C0847A7CE0D6Q33416533-F4D2E5E7-ACF7-480D-8230-063113359370Q33558757-2745B2C1-08A9-4524-BD04-B94518553592Q33664022-CD1F8442-AC4A-4F37-9709-585415B4CD5BQ33713106-4D2C446F-2AC0-4521-B887-7E5F9E1FFACEQ33873518-F2570B54-6325-4EA7-BCF5-6F3CA9757046Q34158874-C559B3B4-9C99-442F-8617-33B6E81FDB84Q34248556-64B7A495-A8B3-4B5D-BB15-ABE35B7B308BQ34418442-32E2FF93-5DD0-4B67-9F19-16359FCB2DACQ34449805-D5747A92-E6A6-4EAC-B130-4EEC6DDA7EF0Q34619308-1C89CD8F-4707-495E-A0C6-7E65E89D9727Q34646321-070DC967-8D6F-4734-91BB-0FD718166093Q34707136-4C7A4237-5C73-4BA1-B4E1-3F6515DF99A5Q35056309-55BCB63D-6B21-418B-87C1-675F26AB697EQ35100217-1A0E7464-D449-449E-917E-E457857C6D1CQ35536558-0C2D6615-D366-4801-A41D-DB9B6C07CFA8Q35798858-F2C8801E-59B0-441B-8D6A-8A9B4F64F07BQ35824964-5EED67A4-BC8A-43DA-972E-74F081A7E723Q36280146-E8F521B8-5EDA-4CEF-9222-9B377729FDCFQ36463900-4B198621-23BB-430C-9C52-63E1048A13F1Q36521854-2DF5E424-77A4-4E9F-A247-5CBF0F2C7C68Q36616696-AE6B7957-B05F-49FF-84D7-99F3B2886510Q36726780-FCD2E028-F7D0-4858-9716-B24C6D72581BQ36807184-146C3697-332E-4DDC-A701-F07D0DB5028CQ36837124-04C17CD1-F8D4-4C94-9CCD-A1A0CE66F207Q36842993-6E9725A0-B881-493D-B542-B12C0D86D549Q36844535-65690088-B820-4088-A818-F3621AD1F3D5Q36879135-6A34F9A0-019A-41B3-B7A3-B2C839C49631Q36910325-15810745-BA0D-4149-9D3E-FA67B92F30BFQ36934350-EB79E23F-E7B5-4C77-A5E2-5D6C8D76BE73Q36961075-91DAF1F5-CF09-4AEB-B859-8166B03B6702Q36967098-7FDD4C93-E7C1-44CD-89D4-40845F34664FQ36967144-C658F43C-6385-492D-9641-6D67AE7AB081Q37059428-EFDDA5D3-765C-4916-8204-0FE31B2BA590Q37083964-22B447FA-B17E-4C21-A84B-7B98C3224BBEQ37194061-6107B918-6852-4012-A1D8-73A718D9099D
P2860
Improved survival of follicular lymphoma patients in the United States.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Improved survival of follicular lymphoma patients in the United States.
@en
Improved survival of follicular lymphoma patients in the United States.
@nl
type
label
Improved survival of follicular lymphoma patients in the United States.
@en
Improved survival of follicular lymphoma patients in the United States.
@nl
prefLabel
Improved survival of follicular lymphoma patients in the United States.
@en
Improved survival of follicular lymphoma patients in the United States.
@nl
P2093
P356
P1476
Improved survival of follicular lymphoma patients in the United States.
@en
P2093
Charles F Lynch
James E Wooldridge
Valerie L Forman-Hoffman
Wade T Swenson
P304
P356
10.1200/JCO.2005.04.503
P407
P577
2005-06-27T00:00:00Z